Marker for lung adenocarcinoma diagnosis and application thereof

A lung adenocarcinoma and metabolic marker technology, applied in the field of detection and diagnosis, can solve the problems of low specificity, single sample source, and low value of early lung cancer screening, and achieve the effect of reducing the risk of trauma and radiation

Pending Publication Date: 2022-01-21
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these studies basically use metabolite information from public databases. Most of the studies have small sample sizes and a single sample source. The screened metabolites are not specific for early lung cancer screening and have little value in actual clinical applications. Big

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for lung adenocarcinoma diagnosis and application thereof
  • Marker for lung adenocarcinoma diagnosis and application thereof
  • Marker for lung adenocarcinoma diagnosis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] This embodiment provides a method for screening metabolic markers for lung adenocarcinoma diagnosis, comprising the following steps:

[0029] S1, collecting samples

[0030]In this study, after obtaining the consent of the patients, peripheral vein samples from 242 patients with lung adenocarcinoma (lung adenocarcinoma group, including 172 patients with early lung adenocarcinoma) and 150 healthy people (healthy group) were collected from Shanghai Chest Hospital. blood serum. Among them, the diagnostic standard for patients with lung adenocarcinoma is confirmed by postoperative pathology. According to TNM staging, patients with stage I and II lung adenocarcinoma were defined as patients with early-stage lung adenocarcinoma. All patients with lung adenocarcinoma and samples from the non-lung adenocarcinoma group had no history of other malignant tumors, no other major systemic diseases, and no chronic medical history of long-term medication. The time of blood collectio...

Embodiment 2

[0076] Example 2: Validation of diagnostic markers for lung adenocarcinoma

[0077] The subjects of this study included 266 serum samples of patients with lung adenocarcinoma from 2 independent medical centers, including 118 patients with early lung adenocarcinoma; and 149 serum samples of healthy people, which were from the same source as the feature screening samples (150 cases) . Among them, the diagnostic standard of lung adenocarcinoma is lung adenocarcinoma diagnosed by postoperative pathology; healthy people are healthy people without lung diseases after physical examination. All lung adenocarcinoma patients and healthy samples had no history of any other malignant tumors, no other major systemic diseases, and no chronic medical history of long-term medication. According to TNM staging, patients with stage I and II lung adenocarcinoma were defined as patients with early-stage lung adenocarcinoma.

[0078] The time of blood collection was in the morning on an empty sto...

Embodiment 3

[0094] Embodiment 3 detection kit

[0095] This embodiment provides a detection kit, comprising:

[0096] (1) Standards for metabolic markers: D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, guanine, gluten Amino acid, creatine, alanine, kynuric acid, each standard product is packaged separately or the standard product mixed solution is packaged.

[0097] (2) Extraction solvent:

[0098] 100% pure methanol and 50% acetonitrile in water for sample preparation;

[0099] 50% acetonitrile in water can be used as a solvent to dissolve the standards.

[0100] (3) Internal standard:: L-phenylalanine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention provides a metabolic marker for diagnosing or monitoring lung adenocarcinoma and a screening method and application of the metabolic marker. A metabolic marker system is selected from one or a combination of more of D-galactose, homocitrulline, N6-acetyl-L-lysine, 4-hydroxy-L-proline, hexadecanedioic acid, guanine, glutamic acid, creatine, alanine and kynuric acid. The metabolic marker provided by the invention can accurately diagnose a lung adenocarcinoma patient, can distinguish an early-stage lung adenocarcinoma patient from a healthy person, is high in sensitivity and strong in specificity, can well replace an existing tissue biopsy and imaging diagnosis mode, and reduces trauma and radiation risks.

Description

technical field [0001] The invention relates to the technical field of detection and diagnosis, in particular to a marker for lung adenocarcinoma diagnosis and its screening method and application. Background technique [0002] According to histopathology, lung cancer is mainly divided into two types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The proportion of non-small cell lung cancer is as high as 85% to 90%. NSCLC further includes lung adenocarcinoma, lung squamous cell carcinoma, and large cell carcinoma. Compared with small cell carcinoma, the growth and division of cancer cells are slower, and the spread and metastasis are relatively late. Among them, the most common subtype of lung cancer is lung adenocarcinoma. Clinically, non-small cell lung cancer is often diagnosed at an advanced stage. More than half of NSCLC patients die within 1 year after diagnosis, and the 5-year survival rate is less than 20%. However, the 5-year survival rate ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/34G01N30/72G01N33/68G01N27/62
CPCG01N30/02G01N30/06G01N30/7266G01N30/34G01N27/62G01N33/6848
Inventor 娄加陶王琳郭巧梅乔理华
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap